Clinical trials: Thromboembolus
Venous Thromboembolism
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
Trauma patients are at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of DVT varies greatly from 5-63% among studies depending on patient's individual risk factors, modality of…
- Trial name
- NCT00531843
- Testing
- fondaparinux sodium, sequential compression devices
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mary Knudson, M.D.
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
- Trial name
- NCT00952380
- Testing
- dalteparin
- Where
- 26 sites in United States, Norway and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Acute DVT of Lower Extremity
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent…
- Trial name
- NCT03465735
- Testing
- Vascular Boot, Standard of Care
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Venous Thromboembolism
EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.
- Trial name
- EINSTEIN Jr (NCT02234843)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Where
- 109 sites in United States, Argentina and 26 more
- Volunteers
- 500 people
- Sponsor
- Bayer
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE), Pulmonary Embolism
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE.
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Trial name
- NCT02798471
- Testing
- Edoxaban, Standard of Care
- Where
- 140 sites in United States, Argentina and 32 more
- Volunteers
- 290 people
- Sponsor
- Daiichi Sankyo
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin The secondary objectives of the…
- Trial name
- NCT05618808
- Testing
- REGN9933, Enoxaparin, Apixiban
- Where
- 16 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 373 people
- Sponsor
- Regeneron Pharmaceuticals
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban…
- Trial name
- NCT00423319
- Testing
- Enoxaparin, Apixaban
- Where
- 143 sites in United States, Argentina and 19 more
- Volunteers
- 5,407 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Venous Thrombosis
Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
The aim of the study is to evaluate efficacy and safety of venous thromboembolism prophylaxis by the combination of graduated compression stockings (GCS), standard doses of low-molecular-weight heparins (LMWH) and sequential…
- Trial name
- IPCSUPER (NCT03044574)
- Testing
- SCD, GCS, LMWH
- Where
- 2 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Pirogov Russian National Research Medical University
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding
Strategies for Anticoagulation During Venovenous ECMO
Moderate intensity titrated dose anticoagulation has been used in patients receiving extracorporeal membrane oxygenation (ECMO) to prevent thromboembolism and thrombotic mechanical complications.
- Conditions
- Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
- Trial name
- SAFE-ECMO (NCT04997265)
- Testing
- Low intensity anticoagulation, Moderate Intensity Anticoagulation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Vanderbilt University Medical Center
Glioblastoma
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
Primary objective: To determine whether aspirin (ASA) can lower the incidence of Venous Thromboembolism(VTE) in patients with Glioblastoma (GBM).
- Trial name
- NCT00790452
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery
The primary objective of this study is to establish the dose-response relationship with regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg b.i.d.
- Trial name
- NCT01225822
- Testing
- Enoxaparin, BIBR 1048
- Where
- 59 sites in Austria, Belgium and 10 more
- Volunteers
- 1,973 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery.
- Trial name
- NCT06118957
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Utah
Wounds and Injuries, Venous Thromboembolism
STAT-STatin and Aspirin in Trauma
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with…
- Trial name
- STAT (NCT02901067)
- Testing
- Aspirin and Rosuvastatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Denver Health and Hospital Authority
Pancreatic Cancer, Venous Thromboembolism
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy.
- Trial name
- NCT00966277
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.
- Trial name
- NCT00523614
- Where
- Germany
- Volunteers
- 3,400 people
- Sponsor
- Center for Epidemiology and Health Research, Germany